FDA Requests New Eye Risk Warnings for Ozempic and Zepbound

The news concerns a request for an eye-risk warning on GLP-1 drugs and is not directly connected to GOOGL's core business model; Alphabet has no revenue from pharmaceuticals or health products. Therefore, its impact on the stock will likely remain limited and indirect. On the technical side, the price is above the SMA20 and SMA50, the RSI is at 57 in neutral-to-positive territory, and the MACD is above its signal line; short-term momentum is slightly positive. However, since the news has a weak sector connection, it is not sufficient to determine direction. Overall, I expect a neutral reaction.

The FDA's request for an eye risk warning for GLP-1 drugs such as Ozempic and Zepbound is a near-term negative news flow for NVO stock. However, technical indicators are already positive: the price is above SMA20 and SMA50, RSI is at 57, and MACD is above the signal line. Therefore, the impact of the news may be limited and selling pressure may be short-lived. The key point to note is that the news is a request for a regulatory warning, not a direct ban or product withdrawal decision. Nevertheless, due to the negative news flow, a slight downward trend can be expected in the short term.

The FDA's request for new eye risk warnings for Ozempic and Zepbound may increase regulatory pressure on GLP-1 class drugs, potentially creating a short-term negative impact on LLY shares. The price is currently slightly above the SMA20 (1389) but below the SMA50 (1400) and in negative territory below the MACD signal line, indicating a weak technical picture. With RSI at 54 (neutral), there is not yet a basis for an oversold rebound. Since the news does not include a direct sales ban or recall, the impact is likely to be limited; however, the headline could dampen risk appetite. I expect downward pressure in the short term, but confidence is moderate.